Fluorescent phospholipid ether compounds, compositions, and methods of use
Inventors
PINCHUK, Anatoly • Weichert, Jamey P. • LONGINO, Marc • Kandela, Irawati • Clarke, William R.
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-9616140-B2
Publication Date
2017-04-11
Expiration Date
Abstract
The invention generally relates to novel fluorescent phospholipid compounds, compositions comprising these compounds, and diagnostic methods utilizing these compounds. A preferred compound of the present invention has the following structural formula:
Core Innovation
The invention relates to fluorescent phospholipid ether tumor-selective diagnostic compounds and their pharmaceutically acceptable compositions. The compounds are disclosed as fluorescent alkyl phospholipid ether analogs with generalized chemical formulas, including preferred compound structures identified as CLR1501 and CLR1502, and selectable fluorophore moieties such as BODIPY or cyanine chromophores.
The compounds are described as existing as different stereoisomers and polymorphs, and as solvated and/or hydrated forms, and also as pharmaceutically acceptable salts. Fluorescence is used as a detection modality, and the compounds are linked to cancer determination by detecting the phospholipid ether compound in a subject.
The disclosure also describes detecting a phospholipid ether compound within an organ of a subject by administering a composition and detecting retention of the phospholipid ether compound within an organ. The use cases include tumor screening, endoscopic visualization, skin lesion detection, aiding biopsy tissue selection, and assessing internal or skin malignancies during surgery through fluorescence imaging.
Claims Coverage
Two independent claims are identified. The claims center on administering a phospholipid ether compound and detecting its presence or retention, with fluorescence and organ-retention readouts as the main inventive features.
Cancer determination by detecting an administered phospholipid ether compound
Administering to a subject a composition comprising a phospholipid ether compound selected from a group and determining cancer in the subject by detecting the phospholipid ether compound in the subject.
Organ retention detection of an administered phospholipid ether compound
Administering to a subject a composition comprising a phospholipid ether compound selected from a group and detecting retention of the phospholipid ether compound within an organ within the subject.
Detecting cancer using fluorescence
The cancer is determined by detecting the phospholipid ether compound in the subject using fluorescence.
Detecting retention using fluorescence
Retention of the phospholipid ether compound within an organ is detected using fluorescence.
The independent claims collectively require administration of a selected phospholipid ether compound and detection-based readouts, including fluorescence, to determine cancer and to detect retention of the compound within selected organs.
Stated Advantages
Tumor-selective fluorescent phospholipid ether diagnostic compounds are described for diagnostic use.
Higher uptake/retention in tumor cells than normal cells.
Clearance from normal tissues over time.
Subcellular localization is described as cytoplasm/lysosomes and lack of nuclear penetration.
Tumor-focused fluorescence.
Documented Applications
Tumor screening and endoscopic visualization.
Selecting biopsy tissue.
Monitoring tumor therapy response, including residual malignant stem cells.
Endoscopic determination of internal malignancy using fluorescence imaging.
Skin lesion determination using fluorescent phospholipid ether compounds.
Assessing internal or skin malignancies during surgery using fluorescence imaging.
Interested in licensing this patent?